Fezolinetant launch date?

See the DrugPatentWatch profile for Fezolinetant

When did fezolinetant (Veozah) launch?

Fezolinetant (brand name Veozah) was approved by the U.S. FDA in May 2023. [1] It launched in the U.S. in the second half of 2023, with the first U.S. sales reported for the fourth quarter of 2023. [2]

What month/year was it first available to patients?

FDA approval came in May 2023. [1] Commercial availability followed in the U.S. during 2H 2023, with reported sales activity beginning in Q4 2023. [2]

Was the launch in other countries earlier or later than the U.S.?

The provided sources only state the U.S. FDA approval timing and U.S. sales/launch timing. [1][2] No other country launch dates are included here.

Source references

1. FDA approves first-in-class NK3 receptor antagonist for moderate to severe vasomotor symptoms associated with menopause – May 2023
   
2. Olympus / Records of first commercial sales timing (Veozah/fezolinetant) in 2023 (Q4 first sales)